The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Looking for synergy or additivity between 188Re and sorafenib on hepatoma cell lines.
Marc Pracht
No relevant relationships to disclose
Nicolas Lepareur
No relevant relationships to disclose
Julien Edeline
No relevant relationships to disclose
Laurence Lenoir
No relevant relationships to disclose
Valerie Ardisson
No relevant relationships to disclose
Bruno Clement
No relevant relationships to disclose
Jean Luc Raoul
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Eveline Boucher
No relevant relationships to disclose
Etienne Garin
No relevant relationships to disclose